## LEE S. MARCUS, M.D., M.S., F.A.C.C.

### Curriculum Vitae

307 E 63<sup>rd</sup> Street New York, NY 10065 (646) 661-2427 drmarcus@pcny.nyc

## PROFESSIONAL EXPERIENCE

President	Preventive Cardiology of NY New York, New York	07/2015-Present
Medical Director/ Chief Science Officer	Optimal Executive/Optimal Wellness Group New York, New York	04/2014-07/2015
Editor in Chief	Empowered Doctor New York, New York	04/2014-07/2015
Director/Analyst	Global Markets Intelligence-Healthcare IPREO, LLC New York, New York	11/2011-03/2014
Medical Director	REVV Medical Diagnostic, PC Ronkonkoma, New York	08/2009-Present
Cardiologist/ Board Member	The Heart Center Poughkeepsie, New York	07/1999-08/2009

## MEDICAL TRAINING

Fellowship	Yale University School of Medicine Yale-New Haven Hospital Nuclear Cardiology	07/1998-06/1999
Fellowship	Yale University School of Medicine Yale-New Haven Hospital Cardiovascular Medicine	07/1996-06/1998
Fellowship	Columbia University Columbia-Presbyterian Medical Center Circulatory Physiology/ Congestive Heart Failure/ Cardiac Transplantation	07/1994-06/1996
Chief Residency/ Residency	New York Medical College Westchester Medical Center Internal Medicine	07/1990-06/1994

## LEE S. MARCUS, M.D., F.A.C.C. C.V., Page Two

### **EDUCATION**

Medical New York Medical College 06/1990

M.D.

Undergraduate Muhlenberg College 06/1986

B.S. (Cum Laude)

Natural Science; Philosophy

Graduate Pace University- Lubin School of Business 05/2014

M.S. as Valedictorian- Finance

### LICENSURE AND CERTIFICATION

M.D. New York State License -188488 03/04/1992

Diplomate American Board of Internal Medicine 1998, 2008

Cardiovascular Disease- Certification

and Recertification

Certification Board of Nuclear 1999, 2009

Cardiology-*Nuclear Cardiology* Certification and Recertification

American Board of Internal Medicine 1993

Internal Medicine-expired

National Board of Medical Examiners 1991

#### **A**FFILIATIONS

Fellow-American College of Cardiology

American Medical Association Heart Failure Society of America

American Society for Preventive Cardiology

National Lipid Association

American Society of Nuclear Cardiology

# LEE S. MARCUS, M.D., F.A.C.C. C.V., Page Three

Cognate Nutritionals

## LEADERSHIP POSITIONS

	Credentials Committee- St. Francis Hospital Poughkeepsie, New York	2004-2009		
	Founder and Medical Director- Congestive Heart Failure Unit/ Congestive Heart Failure Program- Vassar Brothers Medical Center Poughkeepsie, New York	2000-2009		
	Director- Congestive Heart Failure Program- St. Francis Hospital Poughkeepsie, New York	2000-2009		
	Director- Nuclear Cardiology/ Radiation Safety Officer The Heart Center - Poughkeepsie, New York	1999-2009		
	Board President- Dutchess/ Ulster County Chapter- American Heart Association- Poughkeepsie, New York	2006-2008		
	Board Member- The Heart Center Poughkeepsie, New York	2003-2004		
HONORS AND AWARDS				
	Beta Gamma Sigma Business Honor Society	2014		
	Listed in Castle Connolly America's Top Doctors	2006-2009		
	New York State Patient's Choice Award (voted on by patients)	2008, 2009		
	Listed in <b>Hudson Valley Magazine</b> as One of the <i>Top Physicians in the Hudson Valley</i>	2006-2009		
	<b>Key Volunteer Service Award</b> - Dutchess-Ulster Division American Heart Association	2006-2007		
	Most Outstanding Resident Teaching Award New York Medical College	1991, 1992, 1993		
CURRENT CONSULTING POSITIONS				
	Scientific Advisory Board Advanced Facialdontics	11/2015- Present		
	Scientific Advisory Board Xablecath, Inc.	07/2015- Present		
	Medical Advisory Board	06/2015- Present		

## LEE S. MARCUS, M.D., F.A.C.C. C.V., Page Four

**Medical Director** 

07/2014- Present

NFL Alumni Association Wellness Challenge

### PRIOR CONSULTANT AND LECTURER

Gerson Lehrman Group St. Jude Medical Glaxo-Smithkline Astra-Zeneca Scios- Johnson & Johnson

#### BIBLIOGRAPHY/ORIGINAL PAPERS

Marcus, LS: Hart, D; Packer, M; Katz, SD, et al: Hemodynamic and Renal Excretory effects of Human Brain Natriuretic Peptide Infusion in Patients with Congestive Heart Failure: A Double-Blind, Placebo-Controlled, Randomized Cross-Over Trial

Circulation: 1996, 94: 3184-3189

Sun, BC; Catanese, KA; Spanier, TB; Flannery, MR; Gardocki, MT; **Marcus, LS**; Levin, HR; Rose, EA; Oz, MC: 100 Long-Term Implantable Left Ventricular Assist Devices: The Columbia-Presbyterian Experience

Annals of Thoracic Surgery, 1999;68:688-694

#### **ABSTRACTS**

Marcus, LS; Pollack, BD; Corbisiero, R.; Blake, JW; Do Recovery ST-segment Changes Following Exercise Treadmill Testing Enhance Sensitivity and Predictive Value? Clinical Research; Oct. 1993;41:609

Marcus, LS; Yushak, M.; Medina, N; Katz, SD: Assessment of Pulmonary Vascular Reactivity with Human Brain Natriuretic Peptide: Comparison with Nitroprusside

Journal of Heart and Lung Transplantation. 1996; 15:1pt2 S84

Goldstein, D; Choudri, A; Garfein, ES; Flannery, M.; Marcus, LS; Rose, EA; Oz, MC: Experience with Long Term LVAD Support: Implications for Permanent Use

Transplantation 1998; 17 (1):63

Journal of Heart and Lung

Russell, RR; **Marcus, LS**; Rife, F; Tamborlane, WV; Wackers, FJTh; Young, LH; Diminished Cardiac Response to Insulin Induced Hypoglycemia in Patients with Type I Diabetes: **Diabetes** 

#### ADDITIONAL CLINICAL RESEARCH (Partial List)

Effects of Insulin Induced Hypoglycemia on Left Ventricular Function and Autonomic Balance in Diabetic and Non-Diabetic Patients. (Yale University) **1998-1999** 

Randomized Evaluation of Mechanical Assist Therapy in Congestive Heart Failure (**REMATCH Trial**) (Columbia University College of Physicians and Surgeons) **1994-1996** 

## LEE S. MARCUS, M.D., F.A.C.C. C.V., Page Five

Phase II Randomized Multicenter Trial of Twice Daily Deltaparin (Fragmin) versus Intravenous Heparin with Accelerated Infusion of rt-Alteplase (Activase) in Acute Myocardial Infarction (ASSENT PLUS Study) Sub-investigator; 1999-2000

Phase III, Randomized, Open Label Trial Evaluating the Efficacy and Safety of Reopro (Abciximab) in Combination with Reduced Dose Reteplase for Treatment of Acute Myocardial Infarction ( GUSTO IV MI Study) Sub-investigator; 1999-2000

Multicenter, Double Blind Study Comparing the Efficacy and Safety of Long Term Treatment with Valsartan, Captopril and Their Combination in High Risk Patients after Myocardial Infarction (VALIANT Study) Sub-investigator; 1999-2003

Candesartan Cilexitil in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM Study). Principal Investigator; 1999-2003

**Viagra in Congestive Heart Failure and CAD**: A double blind, randomized, placebo controlled, parallel group, multicenter, flexible dose study to evaluate the efficacy and safety of Viagra, in males with erectile dysfunction. **Principal Investigator**; 2001-2002

**SYNERGY**: A Prospective, Randomized, Open Label, Multicenter Study In Patients Presenting With Acute Coronary Syndromes (ACS) Protocol ENO.GMA.301. **Sub-Investigator**; **2002-2004** 

**ADVANCE MI**: Protocol No. 01-042: Addressing the Value of Primary Angioplasty After Combination Therapy or Eptifibatide Monotherapy In Acute Myocardial Infarction. **Sub-Investigator**; 2002-2003

**IMPACT STUDY**: The IMPACT of Medical Subspecialty on Patient Compliance to Treatment with ADVICOR. **Principle Investigator**; 2002

STAMINA-HFP: Registry study of Anemia in a Heart Failure Population. Principle Investigator; 2003

**ACUITY**: A randomized comparison of Angiomax (bivalirudin) versus lovenox/Clexane (enoxaparin) in patients undergoing early invasive management for acute coronary syndromes without ST- segment elevation. **Sub-Investigator**; 2003-2006

**EARLY-ACS:** Early Glycoprotein IIa/IIIb inhibition in Non-ST segment Elevation Acute Coronary Syndrome: A randomized Trial Evaluating the Clinical Benefits of Early Front-Loaded Eptifbatide in the Treatment of Patients with Non-ST segment Elevation Acute Coronary Syndrome. **Sub-Investigator**; **2004-2009** 

**JUPITER:** Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin: A Randomized, Double Blind, Multicenter, Phase III Study of Rosuvastatin (Crestor) 20 mg in the Primary Prevention of cardiovascular Events Among Subjects with Low Levels of LDL-Cholesterol and Elevated Levels of C-Reactive Protein. **Sub- Investigator**; **2005-2008** 

**FUSION II:** Follow-up Serial Infusions of Natrecor (nesiritide) for the Management of Patients with Heart Failure. **Principle Investigator**; 2004-2007

**TRIAL TO ASSESS CHELATION THERAPY (TACT):** grant # 1 UO1 ATOO1156-01 Study Sponsors: National Institutes of Health (NCCAM and NHLBI) **Sub- Investigator**; **2004-2008** 

## LEE S. MARCUS, M.D., F.A.C.C. C.V., Page Six

**USE-BNP STUDY:** Utilizing, Studying, Evaluating BNP for monitoring in subjects with heart failure. Sponsor: Siemens Medical Solutions Diagnostics. **Principle Investigator**; **2007-2009** 

**ASCEND-HF TRIAL:** Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure. **Principle Investigator**; 2007-2009